Patent 11945877 was granted and assigned to Agency for Science, Technology and Research on April, 2024 by the United States Patent and Trademark Office.
Antibodies, antigen-binding fragments and polypeptides that bind to HER2 are disclosed, as well as nucleic acids and vectors encoding the same. Also provided are cells comprising the antibodies, antigen-binding fragments, polypeptides, nucleic acids and vectors, methods of making such molecules, and the use of such molecules for therapeutic applications.